EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

Oral Presentation During the "New Drugs on the Horizon 2" Special Session

ROCKVILLE, Md., April 11, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will present preclinical data for its product candidates ENMD-2076, MKC-1, and ENMD-1198. The data will be presented by EntreMed scientists and collaborators during the American Association for Cancer Research (AACR) Annual Meeting being held April 12-16, 2008 in San Diego, California.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, will give an oral presentation on the Company's selective kinase inhibitor, ENMD-2076, during the special session, "New Drugs on the Horizon 2." EntreMed will share the podium with representatives from leading pharmaceutical companies during this special session which provides early disclosure of new small molecules that are nearing or have recently advanced into clinical trials. Dr. Bray's presentation is scheduled for Sunday, April 13, 2008, at 3:15 p.m.

ENMD-2076 is selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular effects.

In addition, EntreMed scientists are scheduled for the following poster presentations:

     -- "ENMD-1198 Antitumor Activity and Inhibition of HIF-1alpha, STAT3 and

        NFkappaB Signaling Pathways are Dependent on Microtubule Isotype

        Expression and Targeting," Monday, April 14, 2008 from 1:00 PM -

        5:00 PM


     -- "Combination Therapy of MKC-1 and Paclitaxel Synergistically Inhibits

        Tumor Growth in the MDA-MB-231 Orthotopic Breast Cancer Tumor Model,"

        Tuesday, April 15, 2008, 8:00 AM - 12:00 PM.


Dr. Bray's presentation, as well as the poster presentations, will be available on the Company's web site at www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

    CONTACT:

    Ginny Dunn

    Associate Director, Corporate

    Communications & Investor Relations

    EntreMed, Inc.

    240.864.2643

CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643

Web site: http://www.entremed.com/

Ticker Symbol: (NASDAQ-NMS:ENMD)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2008

View comments

Hide
(web5)